Eliciting Preferences for Combination Vaccines Protecting Against Multiple Respiratory Viruses: A Cross-Sectional Discrete Choice Experiment of Adults Aged 50 in the US
Author(s)
Matthieu Beuvelet, PharmD1, Keila Meginnis, Ph.D.2, Caroline de Courville, EMAM1, Maribel Tribaldos, Ph.D.1, Antonio Robles, Ph.D.1, Gabriela Fernandez, MPH3, Hannah Collacott, M.Sc.3, Matthew Quaife, Ph.D.2.
1Sanofi, Lyon, France, 2PPD, Evidera, Thermo Fisher, London, United Kingdom, 3PPD, Evidera, Thermo Fisher, Bethesda, MD, USA.
1Sanofi, Lyon, France, 2PPD, Evidera, Thermo Fisher, London, United Kingdom, 3PPD, Evidera, Thermo Fisher, Bethesda, MD, USA.
OBJECTIVES: Respiratory viruses (RV) including influenza (flu), respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3), are major contributors to respiratory diseases in older populations. Older individuals face complex RV vaccination decisions, choosing between specific viral coverage and broader respiratory illness (RI) protection). This study aimed to understand preferences for RV vaccines in a landscape reflecting both standalone and combination RV vaccines.
METHODS: An online discrete choice experiment (DCE) was fielded with adults aged ≥50 years in the United States. The DCE included seven attributes, identified through a targeted literature review and validated using qualitative interviews, including protection against varying severities of different combinations of RIs. Choice data were analyzed using a mixed logit model; outputs included relative attribute importance (RAI), predicted vaccine choice, and attribute trade-offs.
RESULTS: A sample of 803 participants with a mean age of 63.8 years (SD: 8.0) participated. Protection against severe RI had the largest impact on vaccine decision-making (RAI=22.9%), followed by risk of systemic adverse events (AEs; RAI=21.2%), protection against mild-moderate RI (RAI=21.0%), and risk of local AEs (RAI=14.9%). Viruses protected against (RAI=7.5%), number of shots required (RAI=6.6%), and duration of protection (RAI=6.0%) were less important. An RSV/hMPV combination vaccine was preferred over an RSV standalone vaccine (65% vs. 35%), given efficacy and safety assumptions for each and provided alongside a standalone flu vaccine. Participants were willing to accept two-shot vaccines versus one-shot vaccines in exchange for an increase in protection against RI (+9.3% mild-moderate; +8.9% severe); or a decrease in the risk of side effects (-15.0% local; -10.7% systemic).
CONCLUSIONS: Combination respiratory vaccines, which offer higher overall protection against RI, are valuable to adults aged ≥50 years, underscoring their potential to simplify vaccination schedules and improve coverage, ultimately reducing the burden of RI in this vulnerable demographic.
METHODS: An online discrete choice experiment (DCE) was fielded with adults aged ≥50 years in the United States. The DCE included seven attributes, identified through a targeted literature review and validated using qualitative interviews, including protection against varying severities of different combinations of RIs. Choice data were analyzed using a mixed logit model; outputs included relative attribute importance (RAI), predicted vaccine choice, and attribute trade-offs.
RESULTS: A sample of 803 participants with a mean age of 63.8 years (SD: 8.0) participated. Protection against severe RI had the largest impact on vaccine decision-making (RAI=22.9%), followed by risk of systemic adverse events (AEs; RAI=21.2%), protection against mild-moderate RI (RAI=21.0%), and risk of local AEs (RAI=14.9%). Viruses protected against (RAI=7.5%), number of shots required (RAI=6.6%), and duration of protection (RAI=6.0%) were less important. An RSV/hMPV combination vaccine was preferred over an RSV standalone vaccine (65% vs. 35%), given efficacy and safety assumptions for each and provided alongside a standalone flu vaccine. Participants were willing to accept two-shot vaccines versus one-shot vaccines in exchange for an increase in protection against RI (+9.3% mild-moderate; +8.9% severe); or a decrease in the risk of side effects (-15.0% local; -10.7% systemic).
CONCLUSIONS: Combination respiratory vaccines, which offer higher overall protection against RI, are valuable to adults aged ≥50 years, underscoring their potential to simplify vaccination schedules and improve coverage, ultimately reducing the burden of RI in this vulnerable demographic.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
P46
Topic
Epidemiology & Public Health, Methodological & Statistical Research, Patient-Centered Research
Topic Subcategory
Patient Behavior and Incentives
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines